Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer
Anticancer Research · 2023
DOI: 10.21873/anticanres.16452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Kei Hayashi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Frontotemporal Dementia, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Gastroenterology, Yokohama City University Graduate school of Medicine, Yokohama, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan; m-furuta@kcch.jp.
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
- Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.
Zitieren
APA
Hayashi, K., Furuta, M., Furusawa, K., Hamaguchi, T., Watanabe, M., Inokuchi, Y., Onuma, S., Hashimoto, I., Suematsu, H., Nagasawa, S., Kanematsu, K., Yamada, T., Notsu, A., Ogata, T., Oshima, T., Machida, N., Furuse, J., & Maeda, S. (2023). Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16452
Vancouver
Hayashi K, Furuta M, Furusawa K, Hamaguchi T, Watanabe M, Inokuchi Y, et al. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16452
BibTeX
@article{Hayashi2023,
author = {Hayashi, Kei and Furuta, Mitsuhiro and Furusawa, Kyoko and Hamaguchi, Tomomi and Watanabe, Mamoru and Inokuchi, Yasuhiro and Onuma, Shizune and Hashimoto, Itaru and Suematsu, Hideaki and Nagasawa, Shinsuke and Kanematsu, Kyohei and Yamada, Takanobu and Notsu, Akifumi and Ogata, Takashi and Oshima, Takashi and Machida, Nozomu and Furuse, Junji and Maeda, Shin},
title = {Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16452}
}
EUVIMED